<DOC>
	<DOCNO>NCT02717208</DOCNO>
	<brief_summary>To evaluate safety , local tolerability pharmacokinetic characteristic administration eye-drop HL036 healthy Korean male volunteer</brief_summary>
	<brief_title>Phase 1 Study Safety Tolerability HL036</brief_title>
	<detailed_description>A total 10 subject dose group subject randomize 8:2 HL036 placebo . Three 10 subject randomize sentinel dose group . A safety data review masking perform 3days prior subject treatment . Treatment high dose proceed follow review safety data low dose .</detailed_description>
	<criteria>Subjects listen description characteristic clinical trial sign IRB approve consent form whole screening test Healthy Korean male volunteer 20 50 year old screening procedure Subjects history tuberculosis positive Quantiferon Test Subjects treat live vaccine within 8 week prior first day dose plan treat end study Subjects presence history significant hepatic ( include hepatitis B C ) , renal , neurological , immunological , respiratory , endocrine hemato•oncology , cardiovascular , psychiatric disease Subjects presence history ophthalmological examination follow ① History ocular disease include keratitis , uveitis , retinitis , dry eye , strabismus suspect symptom sign ② Subjects 20/40 correct visual acuity screen ③ Subjects history ocular surgery ( include subject laser surgery previous 6 month screen ) ④ Subjects contact lens wear within 1 month side effect wear , unwilling discontinue wear study period ⑤ Abnormalities follow ophthalmological examination Subjects history allergy antiTNF drug ( infliximab , adalimumab , etanercept ) similar product Subjects history drug abuse positive drug abuse urine test Subjects take prescribed drug , herbal agent within 2 week take overthecounter ( OTC ) drug include artificial tear vitamin within 1 week prior first day dose ( Investigators determine eligibility consider effect drug safety pharmacokinetic result case inclusion/exclusion criterion satisfy . ) Subjects participate another clinical trial bioequivalence research IP within 3 month prior first day dose . Subjects donate whole blood within 2 month component blood within 1 month donate within 1 month prior first day dose . Subjects currently drink excess 21 unit per week ( 1 unit = 10 g pure alcohol ) would able stop drinking alcohol study Subjects smoke 6 month use nicotine product would able stop smoke hospitalization Subjects plan pregnancy use establish contraception ( e.g . infertility operation subject partner , intrauterine contraceptive device partner , barrier contraception , diaphragm condom use combination test Subject judge inappropriate participate clinical trial researcher cause include test result clinical laboratory</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>